AstraZeneca Enters Deal to Acquire Cell Therapy Firm EsoBiotec for Up to $1 Billion

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

AstraZeneca Enters Deal to Acquire Cell Therapy Firm EsoBiotec for Up to $1 Billion

, MT Newswires - 3:53 AM ET 3/17/2025 mergers-and-acquisitions

03:53 AM EDT, 03/17/2025 (MT Newswires) -- AstraZeneca ( AZN ) has agreed to acquire EsoBiotec for a total consideration of up to $1 billion, EsoBiotec said Monday.

The consideration consists of an initial payment of $425 million, and up to $575 million in contingency payments.

The deal includes EsoBiotec's Engineered NanoBody Lentiviral delivery platform which has potential application in cancer therapy, the biotechnology company said.

Closing of the deal is expected to occur in Q2, subject to customary closing conditions.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.